Abstract
Elevations in brain Glx (a combined measure of glutamate and glutamine) are a hallmark of schizophrenia, yet the underlying causes remain poorly understood. This study investigates whether common allelic variants of glutamate-related genes, known to increase the risk for schizophrenia, correlate with these neurochemical elevations. While overall glutamate risk scores did not differ significantly between patients and healthy controls, a distinct relationship emerged in younger patients. These findings suggest that genetic risk manifests as observable chemical imbalances primarily in the early stages of the illness, likely interacting with other genetic or environmental factors.
Introduction
The "glutamate hypothesis" of schizophrenia posits that the disorder is driven by dysfunction in glutamatergic neurotransmission, specifically an overabundance of glutamate in key brain regions. While large-scale genomic studies have identified specific single-nucleotide polymorphisms (SNPs) that increase disease risk, the functional link between these "risk genes" and actual brain chemistry has remained elusive. This study sought to bridge this gap by determining if a summary genetic risk score could predict brain levels of Glx measured via neuroimaging.
Methodology
The researchers employed a multimodal approach combining neuroimaging and genomics in a cohort of 56 clinically stable patients with schizophrenia and 67 healthy controls.
Neuroimaging and Spectroscopy
Proton Magnetic Resonance Spectroscopy ($^1$H-MRS) was performed using a 3-Tesla scanner to measure Glx levels in an axial slab of the brain. The analysis focused on both gray matter (GM) and white matter (WM) voxels. To ensure data integrity, the researchers controlled for tissue fraction and spectral quality (Cramer–Rao lower bounds).
Genomic Risk Scoring
Using an Illumina 5M SNP array, summary risk scores were calculated based on odds ratios from the Psychiatric Genetics Consortium (PGC). Two categories were analyzed:
- Glutamate-related SNPs: Including genes such as GRM3, CLCN3, and SLC38A7.
- Calcium signaling SNPs: Including genes such as CACNA1C and CACNB2.
Data were analyzed using a PROC-MIXED repeated-measures model to account for multiple voxels per subject while controlling for age and tissue type.
Key Results
The Interaction of Age and Genetics
The most significant finding was a specific correlation between genetic risk and brain chemistry in younger patients (≤36 years). In this subgroup, higher glutamate-related risk scores directly predicted higher Glx levels in the gray matter ($p = 0.01$). This relationship was absent in older patients and healthy controls, suggesting that the genetic influence on glutamate metabolism may be most prominent early in the disease course or becomes obscured by chronic illness and medication over time.
Disease-Wide Elevations
Regardless of genetic risk scores, the schizophrenia group as a whole exhibited significantly higher Glx levels in both gray and white matter compared to healthy controls ($p < 0.001$). This indicates that while specific SNPs contribute to the chemical profile, they are part of a broader pathological process. Notably, the correlation was specific to glutamate-related genes; risk scores for calcium signaling genes did not show a similar relationship with Glx levels.
Discussion and Limitations
This study provides a "proof-of-principle" link between genetic predisposition and neurochemical reality. However, several limitations must be considered. The sample size, while robust for an MRS study, is relatively small for genetic association work. Additionally, due to the limitations of the SNP array used, only a subset of targeted glutamate-related genes could be measured.
Future research utilizing higher field strengths (e.g., 7-Tesla) could provide better spectral resolution to separate glutamate from glutamine. Furthermore, investigating epigenetic factors like DNA methylation may reveal how these risk genes are regulated, providing a more comprehensive view of the path from genotype to phenotype in schizophrenia.
Summary updated